364206 | InSolution™ GM 6001 - Calbiochem

364206
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₂₀H₂₈N₄O₄

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      364206-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Catalogue Number364206
          Brand Family Calbiochem®
          References
          ReferencesSolorzano, C.C., et al. 1997. Shock 7, 427.
          Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
          Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
          Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
          Grobelny, D., et al. 1992. Biochemistry 31, 7152.
          Product Information
          ATP CompetitiveN
          FormLiquid
          FormulationA 10 mM (1 mg/257 µl) solution of GM6001 (Cat. No. 364205) in DMSO.
          Hill FormulaC₂₀H₂₈N₄O₄
          Chemical formulaC₂₀H₂₈N₄O₄
          Hygroscopic Hygroscopic
          ReversibleN
          Applications
          ApplicationInSolution™ GM 6001, CAS 142880-36-2, is a 10 mM (1 mg/257 µl) solution of GM6001 in DMSO. A potent, cell-permeable, broad-spectrum inhibitor of MMPs.
          Biological Information
          Primary TargetMMP-1
          Primary Target K<sub>i</sub>400 pM for MMP-1; 500 pM for MMP-2; 27 nM for MMP-3; 100 pM for MMP-8; and 200 pM for MMP-9
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped with Blue Ice or with Dry Ice
          Toxicity Irritant
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          364206

          References

          Reference overview
          Solorzano, C.C., et al. 1997. Shock 7, 427.
          Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
          Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
          Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
          Grobelny, D., et al. 1992. Biochemistry 31, 7152.

          Citations

          Title
        • K. Fredriksson, et al. (2006) Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro. American Journal of Physiology Lung Cellular and Molecular Physiology 290, L326-L333.
        • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
        • Haili Su, et al. (2005) Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision02-July-2008 RFH
          DescriptionA potent broad-spectrum hydroxamic acid inhibitor of matrix metalloproteinases (MMPs). Inhibits MMPs in vitro [Ki = 0.4 nM for skin fibroblast collagenase (MMP-1); Ki = 0.5 nM for gelatinase A (MMP-2); Ki = 27 nM for stromelysin (MMP-3); Ki = 0.1 nM for neutrophil collagenase (MMP-8); and Ki = 0.2 nM for gelatinase B (MMP-9)]. Also prevents the release of TNF-α in vivo and in vitro and abrogates endotoxin-induced lethality in mice.
          FormLiquid
          FormulationA 10 mM (1 mg/257 µl) solution of GM6001 (Cat. No. 364205) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₂₀H₂₈N₄O₄
          Purity≥95% by HPLC
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
          Toxicity Irritant
          ReferencesSolorzano, C.C., et al. 1997. Shock 7, 427.
          Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
          Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
          Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
          Grobelny, D., et al. 1992. Biochemistry 31, 7152.
          Citation
        • K. Fredriksson, et al. (2006) Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro. American Journal of Physiology Lung Cellular and Molecular Physiology 290, L326-L333.
        • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
        • Haili Su, et al. (2005) Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167.